Pharmaceutical spam: Medical disinformation on the internet

Spam advertising of pharmaceutical products is leading patients to seek out information about prescription drugs online, according to a report to be published in the International Journal Business and Systems Research. If those drugs are not available to the internet user through their physician there is a risk that they may obtain such products via illicit means.

The direct advertising of to patients is outlawed in several countries, but spam marketing is all-pervasive and wholly ignores national and international laws. It exists because a sale to even a tiny percentage of the hundreds of millions of people targeted every single day with product offers nets the a profit. Now, Sanjoy Ghose and Vikas Lachhwani of the University of Wisconsin-Milwaukee, have investigated how exposure to spam offering prescription pharmaceuticals motivates individuals to seek additional information on the internet.

Prescription drugs improve health and extend life for many millions of people and it is perhaps natural that patients will seek information about their medication from a variety of sources other than their medical practitioner despite the fact that it is only such a practitioner who can legally prescribe that medication. However, the between patient and pharmaceutical company has changed significantly over the last few decades, and most recently with the advent of the commercial internet and the .

"Over the last few decades, there has been a marked change in the way firms view the patient–drug interface," the team reports. "Patients are now more like 'consumers' and prescription drugs 'consumer products. Marketers now communicate directly with consumers through advertisements where it is legal to do so." There has been much debate over DTCA, direct-to-consumer advertising, but little ongoing discussion of the effect of internet-based communication on consumers. Specifically, there have been very few empirical analyses on the determinants of information seeking over the internet for prescription drugs, the team asserts. They point out that most of the earlier research has focused on consumers' responses in terms of interaction with physicians, and requests for specific drugs after exposure to advertising.

The team's study reveals that exposure to prescription drug spam motivates patients to seek further information over the internet. The reason for this could be the skepticism associated with advertising in general and especially for the case of unregulated spam-based advertising. However, the finding is a double-edged sword as the information seeking might also be associated with attempting to procure prescription medication from sources other than a medical practitioner. The data they report should help move the debate in this area forward and allow policy makers to better determine the impact of marketing on patients.

More information: "Online information seeking for prescription drugs" in Int. J. Business and Systems Research, 2011, 6, 1-17

add to favorites email to friend print save as pdf

Related Stories

Despite some benefit, drug ads can be harmful to your health

Nov 12, 2009

While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize ...

Free e-samples of prescription drugs: At what cost?

Nov 25, 2009

Search the Internet to learn about your asthma, high cholesterol or other common disorder, and odds are you'll be directed to a pharmaceutical company-sponsored Web homepage. There you'll often find an offer for a free sample ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments